THINK INDIA JOURNAL

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

NEW DEVELOPMENTS IN SUBCUTANEOUS SYSTEM OF DELIVERY OF DRUGS

Rakesh kumar Sharma[1*], Amit Mittal[1], Sheetu[1],Sanjeev Kumar Sahu[1],Ravinder khatri[2], Arvind Sharma[2],Mamta sharma[3]

[1]School of Pharmaceutical Sciences,Lovely Professional University,Jalandhar-Delhi G.T.Road,Phagwara,Punjab,India 144411.

[2]Shiva Institute of B.Pharmacy Bilaspur H.P.174004

[3]Chandigarh College of Technology ,Landran,Mohali,Punjab,India.

Email.sharmarakesh846@gmail.com

Abstarct

Subcutaneous delivery of drugs is the application of medication to the skin surface to enter the skin and to achieve adequate concentration systemic circulation to ensure a therapeutic effectiveness. SDDS offers many benefits over traditional system: it offers controlled drug release, prevents first-line symptoms, compliance with clinicians, ease of use and risk elimination and reducing side effects in contrast to conventional treatment. SDDS includes a continuous drugs release system (SDDS). Stratum corneum works as a barrier to the skin penetration and permeation enhancement techniques can overcome this cap. A subcutaneous patch has a few components including the backup membrane, the drug storage tank, the adhesive layer and the lining. This project provides a survey of SDDS and recent developments in SDDS, its benefits over conventional dosage forms, limitations, different parts for subcutaneous patches, subkutaneous patch types, assessment methods, and progress in this field. This is a comprehensive project.

THINK INDIA JOURNAL

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Keywords: SDDS, Stratum corneum, Subcutaneous patch

Introduction:-

One of the preferred routes is the oral path, but with oral route, the liver metabolism, lazy organic disposability and the tendency to produce fast blood spikes leading to repeated dosage[1]. There are drawbacks. Patients forget about taking their medication, and they get tired of swallowing pills even the most faithfully obedient, particularly if they have to take many every day. There is a need to develop new drugs (Gupta et al., 2011) in order to overcome these disadvantages. In 1981, FDA initially licensed subcutaneous patches products. The patches are the measurement structures intended to give a remedially viable measure of medication over the skin of a patient. The subcutaneous medicinal delivery systems are known as patches. Subcutaneous supply leads the way in injecting and oral pathways through increasing patient conformity and avoiding metabolism of the first pass (Shingade et al., 2012). Nicotine activates nicotine for seventeen hours and is one of the most effective patchs, continually removing the smoker's cigarette desire. The scopolamine patch is placed behind the ear and discharges the alkaloid for three days to preven t production by sometimes swallowing the pills. The narcotic fix goes on for 72 hours and gives long haul relief from discomfort. The oestroman-progestin contraceptive patch should be used once in a 7 Days, which means taking one pill each day for women who find it painful (Bhowmik et al., 2010).

The goal of every drugs delivery system is to provide the right site in the body with a sufficient amount of medication to achieve the desired drug concentration promptly. Several novel systems of drug delivery are developed, for example. Intrauterine, subcutaneous and implants etc. Intravaginal. Other methods of drug delivery have contributed to the improvement of the treatment of multiple conditions by improvements in specific pharmacokinetic parameters.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

This delivery system activates the drug at the same time either through zero order kinetics or first o rder kinetics.Since ancient times the application of subcutaneous drugs has been well known. Several ancient cultures were used to treat different symptoms or illnesses through ointments, pastes, plasters and complex inactivities (Ramteke et al., 2012). The subcutaneous conveyance not just gives the consistent controlled organization of the medication,but also enables a continuous entry into the systemic circulation of drugs that have brief biological half-lives, frequently causing undesirable side-effects. Different types of new drug delivery systems, like subcutaneous delivery systems, Controlled release systems, transmucosal delivery systems, etc. (Shingade et al., 2012) have therefore emerged. Patches may likewise limit symptoms, for instance oestradiol patches utilized by more than one million patients every year, without contributing to liver damage, in comparison to oral formulations, in the two main categories-therapeutic and cosmetic), scent patches, skin care patches (a class of patches that measure exposure to sunlight), patches of weight loss, and non-medicated patches in markets where sunlight is exposed.

The dermis comprises a network of capillaries underneath the epidermis, which carry blood across the body. The drug will enter the bloodstream if it crosses the corneal surface of the stratum. This process was referred to as passive diffusion. Lipid soluble compounds can easily pass through the cell membrane intercellular lipid two layers while hydrated intracellular proteins allow Hydrophilic drugs to cross via skin. It is much easier and more effective to use medications in this manner (Nirja et al., 2013).short biological semivasts and avoid the pulse entry, which often lead to unwanted effects on the medication (Gaikwad et al.). Several medicines are being investigated to avoid the restriction commonly encountered in standard dosage forms and to improve their potential. The microenvironnement of the cells and their connection with these new measurements structures was, then again, the need. It led to the old concept of a magic bullet suggested by the dream of Paul Ehrich being brought about by these new technologies (Martinho et al. 2011).2013).

A variety of methods have been tested to improve skin permeability, from chemical / liquid amplifiers to electric fields using iontophoresis and electroporation to ultra-sound or photoacoustic waves. While all mechanisms have different mechanities, they have a similar purpose to break the structure of the stratum of the cornea in order to create the "Holes" which are sufficiently large for

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

molecules to move through. Their route will easily allow the movements of macromolecules, as well as probably supra- molecular complexes and microparticles, and, although they are very large relative to the drug dimensions at a therapeutic distance, remain small (Biradar et al., 2014). (1). They are of magnitude larger than molecular dimensions.

Advantages and disadvantages of subcutaneous drug delivery system

1. Increase in drug bioavailability as first pass metabolism is avoided in this system.
2. Proves to be useful system for drugs which are having low therapeutic index and short half life. Plasma level fluctuation in dose is also lowered.
3. Patient compliance is very high because dosing frequency is reduced.
4. This system is simple delivery system which makes it patient compliance.
5. This system serves as alternate for oral drugs which induces vomiting and diarrhea.
6. Narrow therapeutic index
7. Extended release drug delivery system.
8. Reduction or avoidance of gastric irritation.
9. It increase the staying time of drug inblood.
10. Improve bioavailability.
11. Minimize inter-and intra-patient variation.
    Provide appropriateness for self-management (Bhowmik et al., 2012).

Convenient and painless administration (Patel et al., 2012).

Demerits

1. The dose of drugs is large.

Drugs are sensitive and unpleasant.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Drugs are metabolized in the hair.

Drugs are bound to proteins in the skin.

The product is extremely lipid or water soluble.

Drugs have a greater molecular scale (Hanumanaik et al., 2012).

Pre-systemic digestion The nearness of catalysts in the body, for example, peptidases, can idly process the medication and decrease viability of medication. Numerous medications, particularly those with hydrophilic structures, penetrate the skin too gradually and may not arrive at a helpful level. (Kumar et al., 2015).

Essential components for Designing of subcutaneous delivery of drugs

Polymer matrix or matrices.

The drug.,Permeation enhancers,Pressure sensitive adhesive (PSA),Release liner.

Other excipients (Patil et al., 2012).

Polymer matrix:-Polymer measures the removal of drugs from the body. Possible useful polymers are:

a) organic polymers:-e.g.-Cellulose derivatives, Zein, Gelatin, Shellac, Waxes, Proteins, Gums and their equivalents, Organic rubber, Starch etc.

b) Synthetic elastomers: e.g. Polybutadiene, Hydrine rubber, Polysiloxane, Silicone rubber, Nitrile, Acrylonitrile, Butyl rubber.

c) Synthetic Polymers: e.g. Polyvinyl alcohol, Polyvinyl chloride, Polyethylene, Polypropylene, Polyacrylate, Polyvinylpyrrolidone, Epoxy, Polymethylmethacrylate (Gaikwad, 2013).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Drug:- selection of drug for this system is important aspect, the drug should have all the following properties for a candidate for drug delivery system.

Physicochemical properties:-

Molecular weight-It is important factor for selection of drug. The medication must have molecular weight less than 1000 daltons. The drug having molecular weight more than 1000 daltons is not suitable for this drug delivery system.

Nature of drug:- the drug shoul have both the characteristics I,. hydrophilicity as well a slipophilicity for delivery via this route.

Permeation Enhancers:-

Solvents:- Such mixes can improve infiltration by gulping the polar pathway as well as by fluidizing the lipids. Coming up next are models: fluid heavy drinkers (methanol and ethanol; Alkyl methyl-sulfoxides-dimethyl sulfoxide), Methyl acetamide alkys (MSLA), pyrrolidones-2 pyrrolidones (N-methyl), 2purrolidones; Laurocaprams (Azones)- propylene glycol, glyceroles, silicone fluids, palmitates of isopropyl (Utkarsh et al., 2012).

Surfactantas:- Such molecules, in particular hydrophilic drugs, are thought to improve polar pathways. A surfactant's ability to change penets is determined by the polar head group and the length of the hydrocarbon chain (Utkarsh et al., 2012).

Miscellaneous agents:- These unite urea, a hydrating and keratolytic expert; N, N-dimethyl-m-toluamide; calcium thioglycolate; anticholinergic heads.(Utkarsh et al., 2012).

Qualities of permeation enhancers:-

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

i. It should be non-sensitiveandnon-fotoxic.

. ii. Action should start quickly and activity duration should be predictable and reproducible.

. iii. Do not participate in the body pharmacology.

iv. After the enhancer is removed, the usual barrier properties should be restored immediately and completely.

v. Also organic substances must not be released to the atmosphere through diffusion from the skin in one direction the skin's boundary feature

. vi. All synthetic concoctions and adjuvants to be shaped in topical arrangements and instruments ought to be artificially and physically consistent to accelerants.

. vii. It must be cheap, tasty and colorless.

. viii. The dermatological plans should be formulated readily.

.-ix. It should have an estimated solubility parameter of the hair.

x.It must stick to a proper skin feeling on the skin and spread well (Sachan et al., 2013)

Table1:- Different class of enhancers and their mechanism of action. (Saini et al., 2014)

Sr. No.	CLASS	EXAMPLES	MECHANISM OF ACTION
1.	Hydrating substances	Water occlusive preparations	**Hydrates of SC**
2.	Keratolytics	Urea	**Increase fluidity and hydrates the SC**

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

3.	Organic solvents	Alcohals Polyethylene glycols DMSO	**Partially extracts lipids Replace bound water in the intercellular spaces Increase lipid fluidity**
4.	Fatty acids	Oleic acid	**Increases fluidity of intercellular Lipids**
5.	Terpenes	1,8-cineol, menthol	**Opens up polar pathway**
6.	Surfactants	Polysorbates Sodium lauryl sulphate	**Penetrates into skin, micellar solubilasation of SC**
7.	**Azone**	**1-Dodecylhexahydro-2HAzepine-2on2**	**Disrupts the skin lipids in the both head group and tail region**

.

Pressure sensitive adherence:- The pressurized adhesive (PSA) firmly attaches to the skin the drug delivery system. With just applied finger pressure, she should keep tachy forcefully and forever and utilize a solid holding power. It should also be cleaned without leaving any traces from the smooth surface. Skin compatible adhesives should be removable and minimally irritable without inflecting or leaving any residues. Adhesive must be removable. In addition, they must be willing, without sacrificing their adhésive properties and the skin toleration (Hanumanaik et al. 2012. The most common use of polyacrylates is. Both acrylic adhesives, in general, have a polar character, so that moisture can be readily absorbed and moisturized. It also dissolves most of the substances well and allows high drug charging of polyacrylate matrices such as vinyl, films of polyester, polyester-polypropylene films, polyPropylene resin, polyurethylene resin, Polyurethylene resin, CoTran 9722 movie.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Release liner:- The peel strip protects the finished device from contamination, preventing loss of the drug that is migrated to the adhesive layer during stocking.Typical materials used commonly are polyester foils and other metallic laminates (Gaikwad et al. 2016).

Other excipients:-

a)adhesives:- The weight delicate glue can be mounted on the gadget's face or the gadget's back.i) Simple removal of This.

ii) Don't leave the skin with an unwashing residue.

iii) Excellent skin contact should be provided.

iv) Drug safety physical and chemical.

v) No medication allowed should be affected. Premjeet et al. 2011) (Gupta et al., 2011).

b) Backing layer:- The sponsorship layers are adaptable and offer a not too bad association with the medicine storing tank, confine drugs from entering the estimations type at the top and license printing. It is a clingy material that covers the thing during use on the body, for instance, metallic plastic overlay, plastic fortification with an absorbant layer and an occlusive base plate (aluminum foil), foam sheet (versatile polyurethane).

Recent techniques for enhancement for subcutaneous drug delivery system

Over thousands of years, human civilization has used products as cosmetics and drugs. However, skin use was recognized in the 20th century as a way of delivering drugs. Skin has a number of drug supply restrictions and can not be used for all drug applicants as a route of delivery. SDDS is the desiresd and most frequent route for most drugs because of continuous progress in science and technology. Sub-cutaneous transmission in SDDS64 was categorized into three generations (Jhawat et al., 2013).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Original: it incorporates customary structured patches. These incorporate fundamental tank patches or lattice stickers.Which consist of basic supports, the membrane, the laminate and the adhesive mechanism governing the rate (Jhawat et al., 2013).

Second generation: second generation patches have a single patch added to the permeation enhancers. These penetrations improve the rate of medication and the amount of small molecules of lipophilic drugs on the skin. The permeation enhancer reverses the barrier property by irritating, damaging or disrupting the skin.

Patches of second generation include organic permeation enhancers, solvents, weak heat and physical damage (Jhawat et al., 2013).

Third generation: Patches of the third generation for large hydrophilic drug molecules have been created. Only latest approaches such as ionophoresis, sonophoresis, electropharesis, magnetophoresis and micronedle techniques are used to enable a hormonal distribution via skin patch. The druge molecules can move across the skin or damage the skin externally by these permeation enhancers (Jhawat et al. 2013).

Despite sufficiently high concentrations of medical effectiveness, the most of drugs will not enters the skin. The penetration may be improved by adding a sorption or penetration propagator to drug delivery systems to allow medically beneficial subcutaneous impermeation of most medicines. The following types can be used by such promoters:

Organic solvents:- Because of fractional lixidation of the epidermal liquids, they upgrade the retention of oil dissolvable medications and lead to improved skin status for wetting and transepidermal and transfollicular infiltration. for example dimethyl acetamide, formamide, formamide, cineole, propylene-glycol, cyclohexane, and so forth (Saini et al. 2014). (Saini et al., 2014).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Surface active agents:- The permeation that facilitates the surfactant function is thought to be the product of measures to reduce surface tension, increase skin weighting and enhance the delivery of medications. The most active are anionic surfactants. Their behavior may be because they change the germinative stratum and/or denature the epidermal proteins, for example. their effect. Lauryl sodium and dioctyl sulfo-succinate sodium (Saini et al., 2014). These technology are subcutaneous:

Structured based enhancement techniques

Micro fabricated micro needles

Microneedles

Metered dose subcutaneous spray

Electrically based enhancement techniques

Iontophoresis

Ultrasound

Electroporation

Electroosmosis

Velocity based enhancement techniques

Needle free injection

Intraject

Implaject

Jet Syringes

Lject

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

STRUCTURE BASED ENHANCED TECHNIQUES

Scaled down scale fabricated little scale needles:The Microfabricated microneedles is the instruments which are half and parts of the hypodermic needle and subcutaneous fix utilizing minor needles that can pass on the medicine reasonably. Their little size offers the potential focal points of passing on tremendous substances over the stratum corneum without preposterous torment to the patients. First microneedles structures involved a medicine store and a larger part of projections loosening up from the stock, which enter the stratum corneum and epidermis to pass on the prescription. Microneedle idea utilizes a variety of micron-scale needles that can convey tranquilize into the epidermis and dermis, which eventually prompts take-up by the vessels for foundational conveyance however not so far that microneedles hit the nerves. That is the reason the framework doesn't make patients progressively awkward. Silicium (Larraneta et al. 2016) is the most widely recognized material utilized for needle microfabrication.

Microneedles:- Microneedles (MN) are insignificantly intrusive instruments that travel through the SC layer, enter skin microcirculation and transmit the subcutaneous cycle all through the procedure. The microfabrication systems are utilized to deliver the mN (50–900 mm, up to 2000 MN cm 2) in different geometries and materials (silicon, metal, polymer). MN is added to the outside of the skin and punctures the epidermis easily to prompt little fluid pores, which spread meds through dermal microcirculation. The MN is sufficiently long to arrive at the dermis yet short and flimsy enough to avoid dermal nerve incitement or dermal course perforation.There are no examinations on skin disease generation and we show that patients who are not fitted with outer conveyance frameworks will reproducibly infuse miniaturized scale needles into the body. The empty exhausting smaller scale needle empowers the dispersion or pressurized stream of medications through the focal lumen. In vitro investigations utilizing MN show olionucleotide transmission, hormones, lower insulin blood glucose levels, expanded DNA skin transfection and inspire resistant reaction from DNA and protein antigen conveyance (Larraneta et al., 2016).

Delivery stages of microneedles:-

ISSN: 0971-1260

Vol-22-Issue-17-September-2019



Figure 1. (Larraneta et al., 2016).

Subcutaneous shower portion estimated: Subcutaneous splash estimated in portion estimated (MDSS) is a superior option in contrast to the fix and gel frameworks since the shower shapes the speedy drying, simple to-utilize, adequate and non-occlusive item. Topical pressurized canned products created as single-stage arrangements comprising of prescriptions, polymers and entrance enhancers are the MDSS details. The current growth level of subcutaneous dosage systems (SDDs) has been boosted by recent subcutaneous sprayed commercialized by Acrux Limited (Bakshi et al., 2008). (Bakshi et al., 2008). The formulations for the MDSS have been developed as topical solutions composed of volatile and non-volatile materials found in a single phase drugs and polymers. By integrating the polymers and penetrators into the solvent process, the polymeric

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

sprinkling systems were developed. Within specially designed glass bottles, the drug was specifically measured and the system's weight was modified within full to polymer solvents so as to achieve the desired amount of drug after each actuation (Bakshi et al., 2008).

Electrically based enhancement techniques

IONTOPHORESIS:- The technique includes applying either legitimately or by implication a low-level electric flow to the skin by means of the treatment framework to upgrade pervasion of a topically applied advisor. Nevertheless, iontophoresis supports the permeation of polar drugs with a relatively new percutaneous enhancement technique. There is also a likelihood of establishing a method for the production of the prodrug model based on the synthesis of a prescription iontophoresis precursor to an active drug. Goods that have already entered the US market with iontophoresis, for instance, recently FDA approved a iontophoric product for sale in the US thatis pre-filledandpre-programmed. LidositeTM, this product, provides the local anesthesia for superficial dermatological procedure by providing lidocaine and epinephrine into the skin of intact (Utkarsh et coll., 2011).

ULTRASOUND:- ultrasound involves the use of ultrasound power, often referred to as sonophoresis, to improve the subcutaneous provision of solutes simultaneously or by pretraction. The suggested cause for skin permeability is due to the development, on ultrasound penetration, of gaseous cavities in the intercellular lipids, resulting in disrupting corneal stratum. The most important parameters are known to affect ultrasound absorption such as treatment time, intensity and frequency (Saini and al., 2014).

ELECTOPORATION:- This method involves applying high voltage signals to the skin to cause temporary pores formation. The most common treatments were high voltages (Ž100 V), with brief treatment times (milliseconds). Pulses, such as waveforms, speeds and number, are other electric parameters that influence distribution (Saini et al., 2014).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

ELECTRO-OSMOSIS:- A voltage differential is applied to the porous layer, which has any charge, and therefore a bulk liquid or density stream without concentration gradients exists. This is termed electroosmosis (Saini et al., 2014).

Velocity based enhancement techniques

1.Free needle injection prefilled dispensable injectors are the most noteworthy worth, least created and most innovatively troublesome arrangement of without needle innovation. The design of these methods was driven primarily by the need for a safe and sterile approach for commonly administering needles and syringe (Kumar et al. 2015).

2.Intraject: The nitrogen propellant system with an empty product capsula was one of the prefilled injectors for the reusable intrajectories under Development. Intrajector The client pops the cap, cuts the safety end off and forces the nozzle against pressurized skin air, and drives the liquid through a small aperture into the skin (Kumar et al., 2015).

3. Implaject: Implaject moves the skin before the drug first with a thin, possible "pioneer tip." The tip penetrates the tissue to create a path that immediately follows the therapeutic agent (Kumar et al., 2015).

4. The jet syringe can be designed for a set-dose use by a dose-fillable or patented pre-filled glass ampoula that can administer up to 0.5 ml. Jet syringe: Jet syringe. It is suitable for drug treatments in the short term (Kumar et al., 2015).

5. Iject: Iject model based on Biojector 2000. Iject: The fluid handheld NFI [non-needle gas injectors] is a light weight. Subcutaneous and intramuscular transmission can be between 0.1 and 1.0 mL (Kumar et al., 2015).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

OTHER ENHANCEMENT TECHNIQUES:-

1. **Transfersomes:** The appliance penetrates the cutaneous membrane along the slope of skin moisture. Transfers may create a drug depot with a high drug concentration in the systemic circulation. Transfersomes include a component which destabilizes the bilayers of the lipid and leads to deformable vesicles (Saini et al., 2014).

2. **Medicated Tattoos:** Temporary tattoo alteration that includes a drug active substance for subcutaneous delivery. Health Tattoos: Tattoos For kids who can not take conventional injection forms, this method is helpful in the introduction of the drug (Saini et al., 2014).

3. **Skin abrasion:** It involves removing or disrupting directly on the top layers of the skin so that the topically applied drug substance is better permeated. Normally speeding up the impermeable outer surfaces by using sharp metal particles in microchannels in the skinned (Saini et al. 2014). (Saini et al., 2014).

4. **Laser radiation:** This procedure involves , the skin is exposed to the laser beams and the surface cornea is separated without compromising the connection between the epidermis and the epidermis. This technique enhances lipophilic and hydrophilic drug delivery (Saini et al., 2014).

5. **Controlled CHADD system:** heats are added to the body, which raises the temperature which allows the drug product to circulate in blood and eventually increases the blood vessel microcirculation and permeability. A small heating unit on the top of a conventional patching equipped system (Saini et al., 2014) is part of the CHADD system.

Various strategies for readiness of subcutaneous medication conveyance framework

a). Asymmetric TPX layer strategy: (Prabhakar et al., 2013).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

b). Circular Teflon Mold Method:

Solutions containing polymers of different proportions are used in a natural solvent.Prab hakar et al., 2013).

c). Mercury substrate strategy: (Prabhakar et al., 2013).

d). By utilizing "IPM films" strategy.

e). By utilizing "EVAC layers" strategy: n solicitation to set up the target subcutaneous supportive structure, 1% carbopol store gel, polyethelene (PE), ethylene vinyl acidic corrosive inference copolymer (EVAC) movies can be utilized as rate control layers (Kumar et al., 2010).

f. Aluminum upheld glue film technique: (Kumar et al., 2010).

g). TDDS Preparation by utilizing Proliposomes: The proliposomes are prepared by means of transporter technique using film affirmation strategy (Nirja et al., 2013).

h). By utilizing free film strategy

(Nirja et al., 2013).

Mechanism of activity of subcutaneous medication conveyance framework

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

The capacity of the subcutaneous fix and the progression of the dynamic medication fixing from the fix to the circulatory framework by means of skin come to pass through various techniques.

In order for a fundamentally dynamic drug to reach an objective tissue, it needs to take some physicochemical properties that make the drug's basic sorption through the skin and enter the microcirculation. (Ghulaxe et al., 2015).

Factors affecting subcutaneous medication conveyance

Fick's first law: Drug immersion over the SC conforms to Fick's first law (Equation 1). Thusly the condition helps in perceiving the ideal parameters related with the scattering of prescription over the skin.

$$Dm/do = J = DCo\ P/H$$ (Mbah et al., 2011).

I). Physiochemical factors: The diverse physicochemical properties of prescription which can change the maintenance and scattering of drug through the skin are:

a). Drug particles size and nuclear weight: Size of prescription molecules contrasts oppositely to the passageway through the skin. Medicine particles greater than 500 dalton makes issue in

percutaneous vehicle. Increasingly noticeable the sub-nuclear weight humbler is the digestion.

Therefore, the size of the drug particles should not be high to the point that it causes problems in maintenance. (Jhawat et al., 2013).

b). Partition coefficient: Medications are either water soluble or lipid soluble in nature. The package co-profitable choose the dissolvability or spread of prescription in the structure of the medication competitor without influencing its pharmacological movement of the

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

medication. (Jhawat et al., 2013).

c) Penetrant Fixation: Accepting layer related vehicle, developing get together of slowed down medication causes a looking at growth encountering huge change. At fixation higher than the dissolvability, overabundance strong solution fills in as a vault and keeps up an anticipated medication constitution for a drawn out timeframe (John, 2014).

d). Skin hydration: When it interacts with water the vulnerability of skin augments essentially. Water presence is most critical factor growing the immersion of skin. That was the reason of humectants is done in Subcutaneous transport (Shankar et al., 2013).

e). Temperature and pH: The entrance of drug increase ten folds with temperature assortment. The scatter coefficient falls as the temperature drops. Weak acids and delicate bases separate dependent upon the pH and pKa or pKb values. The degree of unionized drug chooses the medicine center in skin. Thusly, temperature and pH are huge components impacting drug penetration (Shankar et al., 2013).

f). Diffusion coefficient: Dissemination coefficient:
The penetration of the drug depends on the distribution coefficient of the prescription.At a steady temperature the spread coefficient of medicine tons of drug, scattering medium and collaboration between them (Shankar et al., 2013).

II). Biological factors

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

a). **Skin age:** It is normal for young and old skin to be more permeable than modestly matured individuals. In inopportune children stratum corneum is missing and kids are dynamically helpless against harmful effects of prescriptions through the skin (Jhawat et al., 2013).

b).**Blood stream:** Changes in fringe dissemination don't influence subcutaneous retention butan increment in blood stream increment the focus angle over the skin and decreases the all out time of habitation of the medication atoms in the dermis by persistently expelling it (Jhawat et al., 2013).

c). **Hydration of skin:** Due to Hydration of the skin causes the creating of stratum corneum of the skin and gives some smoothness to the skin. Hydration additionally creates the permeant dissolvability and dispersing vehicle to the layer. So the invasion of medication particles happens reasonably through the hydrated skin (Jhawat et al., 2013).

d). **Skin temperature:** When growing the temperature of the skin the percutaneous digestion of the prescription augmentations due to fluidization of lipids and vasodilation of the veins which are in contact with the skin so increase in circulation system to the skin fabricates the maintenance through the skin (Jhawat et al., 2013).

e). **Local Site of skin:** The skin differentiates in anatomical features, for instance, thickness of stratum corneum, number of hair follicles and number of sweat organs per unit surface zone. This qualification may exist from site to site, individual to individual and species to species. So in all cases percutaneous maintenance changes from one another (Jhawat et al., 2013).

f). **Skin absorption:** Skin forms steroids, hormones, compound malignancy causing operators and a couple of prescriptions. So skin absorption chooses practicality of medicine soaked through the skin (Kesarwani et al., 2013).

g). **Species differentiates:** The skin thickness, thickness of furthest points and keratinization of skin move species to species, so impacts the passage (Kesarwani et al., 2013).

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Evaluation of subcutaneous patches

a). **Drug Excipients Interaction Studies:** The medication and excipients ought to be good to create a steady item, and it is compulsory to identify any conceivable physical and concoction cooperation. Collaboration examines are ordinarily completed utilizing warm investigation, FT-IR studies, UV and chromatographic methods by looking at their physiochemical charactersfor example, examine, dissolving endotherms, trademark wave numbers, and ingestion maxima and so forth (Darwhekar et al., 2011).

b). **Drug Content**

c). **Thickness of the fix:**

d). **Weight consistency**

e). **Folding perseverance**

f). **Percentage Moisture content:**

g). **Content consistency test:** Ten patches are picked and substance is settled for particular patches. In case 9 out of 10 patches have content between 85% to 115% of the foreordained worth and one has content at any rate 75% to 125% of the predefined regard, by then subcutaneous patches finish the evaluation of substance consistency. Regardless, if 3 patches have content in the extent of 75% to 125%, by then additional 20 patches are gone after for cure content if these 20 patches have run from 85% to 115%, by then the subcutaneous patches easily get through the appraisal (Raza et al., 2015).

h). **Moisture Uptake:** Gauged films are kept in desiccators at room temperature for 24 h. These are then taken out and showed to 84% relative tirelessness utilizing sprinkled game-plan of

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Potassium chloride in desiccators until an unfaltering weight is practiced (Raza et al., 2015). Percent sogginess take-up is resolved as given underneath

% Moisture take-up = Final weight – early on weight/starting weight X 100

i). **Drug content:** A foreordained area of fix is to be deteriorated in a fitting dissolvable in unequivocal volume. By then the plan is to be isolated through a channel medium and separate the medicine contain with the sensible technique (UV or HPLC system). Every value addresses normal of three unmistakable models (Raza et al., 2015).

j). **Weight Variation:** Uniformity of loads were controlled by gauging five networks of every definition. After each film unit was weighed independently on an advanced parity, the normal load of film was taken as the heaviness of the film (Ramchandani et al., 2012).

k). **Stability Testing :** The subcutaneous movies of ketoprofen was exposed to quickened steadiness learn at (40°C/75% RH) conditions for 90 days, The movies were stuffed in aluminum foil and kept at quickened conditions. The movies were investigated for medicate content at 0, 30, 60 and 90 days individually by an UV spectrophotometer technique (Ramchandani et al., 2012).

l). Permeation Cell: (Ramchandani et al., 2012).

Marketed SDD formulations

Table 2: Marketed Products of Subcutaneous Drug Delivery System

Sr. No.	**Product**	**Active drug**	**Indication**	**References**

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

1	Alora	Estradiol	Postmenstrual syndrome	(Dhiman et., 2011)
2	Androderm	Testosterone	Hypogonadism in males	(Premjeet et al., 2011)
3	Catapres-TTS	Clonidine	Hypertension	(Hanumanaik et al., 2012)
4	Climaderm	Estradiol	Postmenstrual syndrome	(Bhowmik et al., 2012)
5	Climara	Estradiol	Postmenstrual syndrome	(Kumar et al.,2010)
6	CombiPatch	Estradiol/ Norethindrone	Hormone replacement therapy	(Biradar et al., 2014)
7	Deponit	Nitroglycerine	Angina pectoris	(Kumar et al.,2010)
8	Duragesic	Fentanyl	Moderate /severe pain	(Kumar et al.,2010)
9	Estraderm	Estradiol	Post menstrual syndrome	(Premjeet et al., 2011)
10	Fematrix	Estrogen	Post menstrual syndrome	(Premjeet et al., 2011)
11	Fempatch	Estradiol	Post menstrual syndrome	(Hanumanaik et al., 2012)
12	Habitraol	Nicotin	Smoking cessation	(Hanumanaik et al., 2012)
13	Minitrann	Nitroglycerine	Angina pectoris	(Premjeet et al., 2011)
14	Nicoderm	Nicotin	Smoking cessation	(Dhiman et., 2011)
15	Nicotrol	Nicotin	Smoking cessation	(Hanumanaik et al., 2012)
16	Nitrodisc	Nitroglycerine	Angina pectoris	(Kumar et al.,2010)
17	Nitro-dur	Nitroglycerine	Angina pectoris	(Hanumanaik et al., 2012)
18	Nuvelle TS	Estrogen/ progesterone	Hormone replacement therapy	(Kumar et al.,2010)
19	Ortho-Evara	Norelgestromin/estradiol	Birth control	(Kumar et al.,2010)

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

20	Prostep	Nicotine	Smoking cessation	(Hanumanaik et al., 2012)
21	Testoderm TTS	Testosterone	Hypogonadism in males	(Premjeet et al., 2011)
22	Transderm Scop	Scopolamine	Motion sickness	(Premjeet et al., 2011)
23	Transderm	Nitroglycerine	Angina pectoris	(Premjeet et al., 2011)
24	Esclim	Estradiol	Hormone replacement therapy	(Dhiman et., 2011)
25	Lidoderm	Lidocaine	Anesthetic	(Premjeet et al., 2011)
26	Vivelle	Estradiol	Post menstrual syndrome	(Bhowmik et al., 2012)
27	Matrifen	Fentanyl	Pain relief patch	(Dhiman et., 2011)
28	Nu Patch 100	Diclofenac Diethylamine	Anti-inflammatory	(Bhowmik et al., 2012)
29	Oxytroll	Oxybutynin	Overactive bladder	(Dhiman et., 2011)
30	Iontocaine	Lidocaine/epinephrine	Local dermal analgesic	(Dhiman et., 2011)
31	Synera	Lidocaine/tetracaine	Local dermal analgesic	(Hanumanaik et al., 2012)
32	Ionosys	Fentanyl	Acute postoperative pain	(Bhowmik et al., 2012)
33	Daytrana	Methylphenidate	Attention deficit hyperactivity	(Bhowmik et al., 2012)
34	Emsam	Selegiline	Major depressive	(Hanumanaik et al., 2012)
35	Neupro	Rotigotine	Parkinson’s disease	(Bhowmik et al., 2012)
36	Exelon	Rivastigmine	Dementia	(Bhowmik et al., 2012)
37	Zecuity	Zecuity	Migraine	(Bhowmik et al., 2012)

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Conclusion and Future aspects: Subcutaneous medication conveyance is an effortless, advantageous, and conceivably powerful approach to convey numerous medications all the time.Wide range of medications can be administered with increased penetration of drugs Minimal risks and side effects are Less and ecomoicalThe impacts of the medication, the highlights of the skin and the condition of the patient's skin are terrifically significant components for a protected and viable treatment.In ongoing years the usage of different biophysical procedures has bolstered in our understanding of the possibility of the stratum corneum impediment and the way by which manufactured mixtures partner with and sway this structure. An unrivaled cognizance of the coordinated effort of enhancers with the stratum corneum and the headway of structure development associations for enhancers will help in the arrangement of enhancers with perfect properties and immaterial harmful quality.Subcutaneous medication conveyance is not really an old innovation, and the innovation never again is simply cement patches. Because of the ongoing advances in innovation and the consolidation of the medication to the site of activity without cracking the skin film subcutaneous course is turning into the most broadly acknowledged course of medication organization. It vows to dispense with needles for organization of a wide assortment of medications later on. SDDS have mind blowing potential outcomes, having the choice to use for both water loving and lipid loving powerful substance into promising deliverable drugs. Because of the ongoing developments in innovation and the consolidation of the medication to the site of activity without cracking the skin layer subcutaneous course is turning into the most broadly acknowledged course of medication organization and numerous new explores are progress nowadays to join more up to date tranquilizes by means of the framework. To advance this medication conveyance framework, more prominent comprehension of the various instruments of organic connections, and polymer are required.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

References

1. Upadhyay G, Verma S, Parvez N, Sharma PK. Recent trends in subcutaneous drug delivery system - a review. Adv. Biol. Res. 2014; 8(3): 131-138.
2. Gupta V, Yadav SK, Dwivedi AK, Gupta N. Subcutaneous drug delivery: Past, present, future trends. Int. J Pharm. Life Sci. 2011; 2(9): 1096-1106.
3. Patel D, Chaudhary AS, Parmar B, Bhura N. Subcutaneous drug delivery system: A review. Pharm. Inno. 2012; 1(4): 66.
4. Shingade GM, Quazi A, PM Sabale, ND Grampurohit, MV Gadhave, SL Jadhav, DD Gaikwad. Review on: Recent trend on subcutaneous drug delivery system. J. Drug Deliv. Thera. 2012, 2(1):66.
5. Gaikwad AK. Subcutaneous drug delivery system: Formulation aspects and evaluation. Comp. J. Pharm. Sci. 2013; 1(1): 1-10.
6. Bhowmik D, Chiranjib, Chandira M, Jayakar B, Sampath KP. Recent advances in subcutaneous drug delivery system. Int. J. Pharma. Res. 2012; 2(1): 68-77.
7. Nirja, Jalwal P, Sigroha S, Kumar S. Recent advances on subcutaneous drug delivery system. Int. J. Phar. Prof. Res. 2013; 4(2): 840-850.
8. Martinho N, Damg C, Reis C. Recent advances in drug delivery systems. J. Biom. Nanobio. 2011; 2: 510-526.
9. Bhowmik D, Duraivel S, Kumar KPS. Recent trends in challenges and opportunities in subcutaneous drug delivery system. Phar. Inno. J. 2012; 1(10): 9-23.
10. Ramteke KH, Dhole SN, Patil SV. A Review: subcutaneous drug delivery system. J. Adv. Sci. Res. 2012; 3(1): 22-35.
11. Biradar DD, Sanghavi N. Technologies in subcutaneous drug delivery system. Int. J. Pharm. Che. Sci. 2014; 3(2): 528-540.
12. Chein YW. Novel drug delivery system: subcutaneous controlled-release drug administration fundamental development concepts and biochemical applications. Adv.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Biol. Res. 2014; 8(3): 131-138.

13. Mali AD, Bathe R, Patil, MK.An updated review on subcutaneous drug delivery systems. Int. J. Adv. Sci. Res. 2015; 1(6): 244-254.
14. Saini N, Bajaj A. Recent trend on subcutaneous drug delivery system and advancements in drug delivery through skin. Int. J. Res. Pharm. Bios. 2014; 4(1): 5-14.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

15. Patil PM, Chaudhari PD, Patel KJ, Kedar KA, Katolkar PP. Recent trends in challenges and opportunities of subcutaneous drug delivery system. Int. J. Drug Dev. Res. 2012; 4(1): 39-50.
16. Hanumanaik M, Patil U, Kumar G, Patel SK, Singh I, Jadatkar K. A Review: design, evaluation and recent trends in subcutaneous drug delivery system. Int. J. Pharm. Sci. Res. 2012; 3(8): 2393-2406.
17. Kumar P, Saini S, Singh G, Benerjee A. A review on potential for recent trends on subcutaneous drug delivery system. Int. J. Rec. Adv. Phar. Res. 2015; 5(3): 224-236.
18. Utkarsh PS, Hemant BP, Shashikant DB, Yogesh KP, Mahendra JR, Ravikiran NS, Yogesh SA, Akash KP. Recent advances in subcutaneous drug delivery system. J. Pharm. Res. 2012; 5(1): 447-456.
19. Sachan R, Bajpai M. A Review: subcutaneous drug delivery system. Int. J. Res. Dev. Phar. Life Sci. 2013; 3(1): 748-765.
20. Premjeet S, Bilandi A, Sahil K, Akanksha M. Transdemal drug delivery system patches, applications in present scenario. Int. J. Res. Phar. Che. 2011; 1(4): 2231-2781.
21. Modi CD, Bharadia PD. Transfersomes: new dominants for subcutaneous drugs delivery. Am. J. Pharm. Tech. Res. 2014; 2(3): 71-91.
22. Prajapati ST, Patel CG, Patel CN. Transfersomes: A vesicular carrier system for subcutaneous drug delivery. Asi. J. Bioc. Pharm. Res. 2011; 2(1): 507-524.
23. Jain NK. “Controlled and novel drug delivery” Ist ed. CBS Adv. Biol. Res. 2014; 8(3): 131-138.
24. Storm JE, Collier SW, Stewart S. “Metabolism of xenobiotics during percutaneous penetration: role of absorption rate and cutaneous enzyme activity. Fundam. Appl. Toxicol 1990; 2(1): 132–41.
25. Loyd V, Allen JR, Nicholas G, Popovich, Howard C, Ansel. Pharmaceutical dosage forms and drug delivery systems, 8th Ed. Wolter Kluwer Publishers, New Delhi, 2005: 298-299.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

26. Kumar R, Philip A. Modified Subcutaneous Technologies: breaking the barriers of drug permeation via the skin. Trop. J. Pharm. Res. 2007; 6(1): 633-644.
27. Kumar P, Sankar C, Mishra B. Delivery of macromolecules through skin. Ind. Pharm. 2004; 5(3): 7-17.
28. Robinson JR, Lee HL. Controlled drug delivery fundamentals and applications 2nd edi, Marcel Dekker New York 1987: 524-552.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

29. Singh MC, Naik AS and Sawant SD. A Review: subcutaneous drug delivery systems with major emphasis on subcutaneous patches. J. Pharm. Res. 2010; 3(10): 2537-2543.
30. Ghosh TK, Jasti BR, Abraham W. Subcutaneous and topical drug delivery systems. Theory and practice of contemporary pharmaceutics 2004: 423-454.
31. Haag R, Kratz F. Polymer Therapeutics: concepts and applications. Ang. Chem. Int. Ed. 2006; 8(45): 1198-1215.
32. Brown BM, Matthew JT, Gary PM, Franklin KA. Subcutaneous drug delivery systems. Skin perturbation devices.
33. Prausnitz MR. Micro needles for subcutaneous drug delivery. Adv. Drug Delivery Reviews. 2004; 56: 581-587.
34. Prausnitz MR, Langer R. Subcutaneous drug delivery. Nat. Biotechnol. 2008; 26(11): 1261-1268.
35. Wilkosz MF. subcutaneous drug delivery. Jobson publication 2003.
36. Yamamoto T, Katakabe K, Akiyoshi K, Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. Diabetes Res. Clin. Pract. 1990; 8: 19-22.
37. Rhaghuram RK, Muttalik S, Reddy S. Once – daily sustained- release matrix tablets of nicorandil: formulation and *invitro* evaluation. Aaps Pharm. Scitech. 2003; 4(4): 480–488.
38. Sandhu P, Ajay B, Kataria S, Middha A. Transdemal drug delivery system (patches), applications in present scenario, Int. J. Res. Phar. Che. 2011; 1(4): 56-78.
39. Harunusman P, Upendra P, Patel D, Daslaniya BB, Ghanshyam P, Dhiren B. Subcutaneous drug delivery system as prominent, dosage forms for the highly lipophillic drug. Int. J. Phar. Res. Bio. Sci. 2012; 1(3): 42-65.
40. Latheeshjlal L, Phanitejaswini P, Soujanya Y, Swapna U, Sarika V, Moulika G.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

Subcutaneous drug delivery systems: an overview Int. J. Pharm. Res. Int. Fr. 2012; 3(4): 2140-2148.

41. Howard, Ansel C, Allen LV, Popovich NG. Pharmaceutical dosage forms and drug delivery ystems. 5th ed: 311-312.
42. Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics A Teatise. Vallabh Prakashan Delhi 1995: 495-497.

Vandana Y, Sipai A, Mamatha M, Prasanth VV. Subcutaneous drug delivery: a technical writeup. J. of Pharm.and Sci. Inn. 2012; 1(1): 5-12.

43. Valenta C, Auner BG. The use of polymers for dermal and subcutaneous delivery. Eur. J. Pharm. Sci. 2012; 58: 279-289.
44. Alexande AR, Dwivedi S, Ajazuddin, Giri TK, Saraf S, Tripathi DK. Approaches for breaking the barriers of drug permeation through subcutaneous drug delivery, J. Controlled Release 2013; 164: 26-40.
45. Vishwakarma SK, Niranjan SK, Irchhaiya R, Kumar N, Akhtar A. A novel subcutaneous drug delivery system. Int. J. of Res. Pharma. 2012; 3(8): 39-44.
46. Rastogi V, Yadav P. Subcutaneous drug delivery system: An overview. Asi. J. Pharm. 2012; 6(3): 161-170.
47. Arunachalam A, Karthikeyan M, Kumar V, Prathap M, Sethuraman S, Ashutoshkumar S, Manidipa S. Subcutaneous drug delivery system: A Review. Current Pharm. Res. 2012; 1(1): 70-81.
48. Sharma N, Agarwal G, Rana AC. Ali B, Kumar D. A review: subcutaneous drug delivery system: a tool for novel drug delivery system. Int. J. Drug Dev. Res. 2011; 3(3) 70-84.
49. Jain NK. Introduction to novel drug delivery systems. subcutaneous drug delivery: 97-117.
50. Kumar D, Patel M. Design and evaluation of subcutaneous drug delivery of an antihypertensive drug: Nicardipine hydrochloride. Rajiv Gandhi University of health

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

sciences 2011 Karnataka (dissertation).

51. Pocius AV. Adhesives In: Howe- Grants M, Ed. Kirk-Othmer Encyclopedia of chemical technology. New York, Wiley-Interscience; 1991: 445-466.
52. Walters KA. Subcutaneous drug delivery systems. Encyclopaedia of pharmaceutical technology. New York, Marcel Dekker Inc; 1997.
53. Allen LV, Popuich NG, Anse HW. Ansel's pharmaceutical / dosage forms and drug delivery system published by Lippincott Williams & wilkis, 8th Ed. 298-313.
54. Larraneta E, Lutton EM R, Woolfson AD, Donnelly RF. Microneedle arrays as subcutaneous and intradermal drug delivery systems: Materials science, manufacture and commercial development. Materials Science and Engineering 2016: 1–32.
55. Chaudhri BP, Ceyssens F, Guan T, Manna AL, Neves HP , Hoof CV, Puers R. High strength, polymer microneedles for subcutaneous drug delivery. Procedia Eng. 2011; 25: 1377 – 1380.
56. Bakshi A, Bajaj A, Malhotra G, Madan M, Amrutiya N. A novel metered dose subcutaneous spray formulation for oxybutynin. Int. J. Pharm. Sci. Res. 2008; 70(6): 733–739.
57. Liao Ai-Ho. Ultrasound in biomedical engineering: ultrasound microbubble contrast agents promote subcutaneous permeation of drugs. J. Med. Ultrasound 2016; 24: 86-88.
58. Prabhakar D, Sreekanth J, Jayaveera KN. A review: subcutaneous drug delivery patches. J. drug delivery Ther. 2013; 3(4): 213-221.
59. Kumar JA, Pullakandam N, Prabu SL, Gopal V. An Overview: subcutaneous drug delivery system. Int. J.of pharm. Sci. Res. 2010; 3(2): 49-51.
60. Ellen JW. Three Generation: The past, present and future of subcutaneous drug delivery systems. Pharm. Edu. Cos., 2011; 1 (2): 1-22.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

61. Marie-Laure L, Herve R, Patrick W, Richard HG. Formulation and evaluation of testosterone subcutaneous spray. J. Pharm. Sci. 2006; 95: 1693-702.
62. Morgan TM. Metered dose subcutaneous spray (MDTS). In: Hagraft J, editor. Modified release drug delivery technology 2003: 523-31.
63. Wein AJ, Rackley RR. Overactive bladder: A better understanding of pathophysiology, diagnosis and management. J. Urol. 2006; 175: 5-10.
64. Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. Wor. J. Urol. 2001; 19: 319-323.
65. www.pharmainfo.net/…/overactive-bladder-disease-overview-recentadvances- symptoms-diagnosis-and-treatment
66. Shih CP, Chen HC, Chen HK. Ultrasound-aided microbubbles facilitate the delivery of drugs to the inner ear via the round window membrane. J. Con. Rel.. 2013; 167: 167–174.
67. Madhuri N, Bhargav E, Anand M, Ravi V, Ramesh K. Subcutaneous drug delivery system a review. Wor. J. phar. Pharm. Sci. 2013; 3(1): 170-186.
68. Peeush S, Ritu S, Vipin K, Kapil GK, Ashish J, Rajendra Y. Subcutaneous drug delivery system: a novel technique to enhance therapeutic efficacy and safety of drugs. American
J. Pharm. Tech. Res. 2012.
69. Suryakanta S, Sarwar B, Astha S, Niranjan PC, Rao M, Bhanoji E. Advanced techniques for penetration enhancement in subcutaneous drug delivery system. Curr. Drug Deliv. 2011; 8(4): 456-73.
70. Kamal G, Anu G, Taruna G, Singh K. Subcutaneous drug delivery- A Review. Int. J. Res. Pharm. Sci. 2012; 3(3): 379-388.
71. Aqil M, Sultana Y, Ali A. Matrix type subcutaneous drug delivery systems of metoprolol tartrate. Acta. Pharm. 2003; 53: 119-125.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

72. Sridevi S, Chary MG, Krishna DR, Prakash V, Diwan. Pharmacodynamic evaluation of subcutaneous drug delivery system of glibenclamide in Rats. Indian J. Phar. 2000; 32: 309-312.
73. Teja S, Gaurav R. Subcutaneous therapeutic systems: An overview. Int. J. Pharm. Bio. Arc. 2011; 2(6): 1581-1587.
74. Wiechers J. Use of chemical penetration enhancers in subcutaneous drug delivery-possibilities and difficulties. Act. Pharm. 1992; 4: 123.
75. Rani S, Saroha K, Syan N, Mathur P. Subcutaneous patches a successful tool in subcutaneous drug delivery system: An overview. Der. Pharm. Sinica. 2011; 2 (5): 17-29.
76. Al-Khamis K, Davis SS, Hadgraft J. Microviscosity and drug release from topical gel formulations. Pharm. Res. 1986; 3: 214-217.
77. Anon. Subcutaneous delivery systems-general drug release standards. Pharm. Forum. 1980; 14: 3860-3865.
78. Mayorga P, Puisieux F, Couarraze G. Formulation study of a subcutaneous delivery system of primaquine. Int. J. pharm. 1996; 132: 71-79.
79. Deo MR, Sant VP, Parekh SR, Khopade AJ, Banakar UV. Proliposome-based subcutaneous delivery of levonorgestrel. J. Bio. Appl. 1997; 12: 77-88.
80. Yan-yu X, Yun-mei S, Zhi-Peng C and Qi-nerg P. Preparation of silymarin proliposomes: A new way to increase oral bioavailability of silymarin in beagle dogs. Int. pharm. 2006; 319: 162-168.
81. Ghulaxe C, Verma R. A review on subcutaneous drug delivery system. The Pharma. Inn. J. 2015; 4(1): 37-43.
82. Darwhekar G, Jain DK, Patidar VK. Formulation and evaluation of subcutaneous drug delivery system of clopidogrel bisulfate. Asi. J. Phar Life Sci. 2011; 1(3): 269-275.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

83. Raza R, Mittal A, Kumar P, Alam S, Prakash S, Chauhan N. Approaches and evaluation of subcutaneous drug delivery system. Int. J. Drug Dev. Res. 2015; 7(1): 222-233.
84. Ramchandani U, Balakrishnan S. Development and evaluation of subcutaneous drug delivery system of ketoprofen drug with chitosan for treatment of arthritis. Eur. J. App. Sci. 2012; 4(2): 72-77.
85. Patel DM, Kavitha K. Formulation and evaluation aspects of subcutaneous drug delivery system. Int. J.Pharm. Sci. Rev. Res. 2011; 6(2): 83-90.
86. Amjad M, Ehtheshamuddin M, Chand S, Hanifa, Sabreesh M, Asia R, Kumar GS. Formulation and evaluation of subcutaneous patches of atenolol. Adv. Res. In Pharm. Biol. 2011; 1(2): 109-120.
87. Humama F, Shalini S. Development and evalution of subcutaneous therapeutic system of an antihypertensive drug. Int. Res. And J. Pharm. 2015; 6(3): 213-217.
88. Jhawat VC, Saini V, Kamboj S, Maggon N. Subcutaneous drug delivery systems: approaches and advancements in drug absorption through skin. Int. J. Pharm. Sci. Rev. Res. 2013; 20(1): 47-56.
89. Shankar PB, Manohar SD, Bhanudas SR. Patches: A novel approach for development of topical drug delivery system. J. Adv. Phar. Edu. Res. 2013; 3(4): 348-356.
90. John L. Review on subcutaneous drug delivery system. Int. J. Pharm. Res. Health Sci. 2014; 2(4): 261-272.
91. Kesarwani A, Yadav AK, Singh S, Gautam H, Singh HN, Sharma A, Yadav C. Theoretical aspects of subcutaneous drug delivery system. Bul. Pharm.Res. 2013; 3(2): 78-89.
92. Mbah CJ, Uzor PF, Omeje EO. Perspectives on subcutaneous drug delivery. J. Chem. Pharm. Res. 2011; 3(3): 680-700.
93. Keleb E, Sharma RK, Mosa EB, Aljahwi A-AZ. Subcutaneous drug delivery system design and evaluation. Int. J. Adv. in Pharm. Sci. 2010; 1: 201-211.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

94. Baichwal MR. Polymer films as drug delivery systems. Advances in drug delivery systems Bombay, MSR Foundation; 1985; 136-147.
95. Vyas SP, Khar RK. Targetted and controlled drug delivery system. 1st ed. CBS Publishers and distributors New Delhi; 2002; 411- 447. .
96. Singh J, Tripathi KT, Sakia TR. Effect of penetration enhancers on the in vitro transport of ephedrine through rate skin and human epidermis from matrix based subcutaneous formulations. Drug. Dev. Ind. Pharm. 1993; 19: 1623-1628.
97. Ryan D. Gordon, and Tim A. Peterson, subcutaneous drug delivery, drug delivery technology. www.drugdeliverytechnology.com.
98. Scheuplein RJ, Blank IH, Brauner GJ and MacFarlane DJJ. Invest. Dermatol. 1969; 52: 63-70.
99. Prakash UR, Thiagarajan P. Subcutaneous drug delivery systems influencing factors, study methods and therapeutic applications. Int. J. Pharm. 2012; 2(2): 366-374.
100. Govil SK, Tyle P. Drug delivery: fundamentals and application. 2nd ed. New York Marcel Dekker 1998: 385-406.
101. Jalwal P, Jangra A, Dahiya L, Sangwan Y, Saroha R. A review on subcutaneous patches. The Pharma. Res. 2010; 3: 139-149.
102. Aulton ME. Pharmaceutics the science of dosage form design. elsvier publisher 2002; 2: 499-533.
103. Sharma N, Agarwal G, Rana AC, Bhat ZA, Kumar D. A review: subcutaneous drug delivery system: A tool for novel drug delivery system. Int. J. Drug Dev. Res. 2011; 3(3): 70-84.
104. Shivaraj A, Selvam RP, Mani TT, Sivakumar T. Design and evaluation of subcutaneous drug delivery of ketotifen fumarate. Int. J. Pharm. Biomed. Res. 2010; 1(2): 42-47.
105. Bharkatiya M, Nema RK. Design and characterization of drug free patches for

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

subcutaneous application. Int. J. Pharm, Sci. 2010; 2 (1): 35-39.

106. Ramkanth S, Alagusundaram M, Gnanaprakash K, Rao KM, Mohammed STS, Paneer K, Chetty MC. Design and characterization of matrix type subcutaneous drug delivery System using metoprolol tartarate. Int. J. Pharm Res. 2010; 1 (1) 1-5.
107. Sanjoy M, Thimmasetty J, Ratan GN, Kilarimath BH. Formulation and evaluation of Crvedilol subcutaneous patches. Int. Res. J. Pharm. 2011; 2 (1): 237-248.
108. Patel JH, Patel JS, Desai BG, Patel KD. Design and evaluation of amlodipin besilate subcutaneous patches containing film former. Int. J. Pharm. Res. Dev. 2009; 7: 1-10.
109. Keleb E, Sharma RK, Mosa EB. Subcutaneous drug delivery system-design and evaluation. Int. j. Of adv. in pharm. Sci. 2010; 1: 201-211.
110. Aggrawal G, Dhawan S. Development, fabrication and evaluation of subcutaneous drug delivery system a review. pharmainfo.net 2009; 7(5).
111. Raghuram RK, Muttalik S, Reddy S. Once –daily sustained release matrix tablets of nicorandil formulation and invitro evaluation. Pharm. scitesch. 2003: 480-488.
112. Shaila L, Pandey S, Udupa N. Design and evaluation of matrix type membrane controlled subcutaneous patch. Int. J. Pharm. 2012; 2(2): 366-374.
113. Mondol S, Thimmasetty J, Ratan GN, Kilarimath BH. Formulation and evaluation of carvedilol subcutaneous patches. Int. Res. J. Pharm. 2011; 2 (1): 237-248.
114. Gupta JRD, Irchhiya R, Garud N, Tripathi P, Dubey P, Patel JR. Formulation and evaluation of matrix type subcutaneous patches of Glibenclamide, Int. J. Pharm. Sci Drug Res. 2016: 46-50
115. NK. Jain. Controlled and Novel Drug Delivery. CBS Pvt. Ltd, ed. I 1997: 118-127.
116. Aarti N, Louk AR, Russsel OP, Richard HG. Mechanism of oleic acid induced skin permeation enhancement in vivo in humans. J. control. Release. 1995; 37: 299-306.
117. Aggarwal G, Dhawan S. Development, fabrication and evaluation of subcutaneous drug delivery system - A review. Int. J. Pharm. 2012; 2(2): 366-374.

ISSN: 0971-1260

Vol-22-Issue-17-September-2019

118. Singh J, Tripathi KT, Sakia TR. Effect of penetration enhancers on the in vitro transport of ephedrine through rate skin and human epidermis from matrix based subcutaneous formulations. Drug. Dev. Ind. Pharm. 1993; 19: 1623-1628.
119. Gordon R, Tim D, Peterson A. Subcutaneous drug delivery, drug delivery technology. www.drugdeliverytechnology.com
120. Hafeez A, Jain U, Singh J, Maurya A, Rana L. An overview: recent advances in subcutaneous drug delivery system (Tdds). J. sci. inn. Res. 2013; 2 (3): 733-7